Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

nsing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... Applications , the global market for industrial enzymes is ... registering a five-year compound annual growth rate (CAGR) of ... the detergent enzyme segment with a CAGR of 11.3% ... almost every sector of industrial activity, ranging from technical ...
(Date:7/30/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... Outstanding Issues (LOI) from the European Medicines Agency,s Committee ... NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release ... being evaluated for weight loss. The key ... adequately addressed by the Company based in part on ...
(Date:7/30/2014)... 30, 2014   Epic Sciences, Inc. ("Epic"), ... diagnostics to personalize and advance the treatment and management ... T. Lucier as chairman of Epic,s board of ... Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board ... circulating rare cell analysis platform with special focus on ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... NORTH BILLERICA, Mass., Sept. 9 Seahorse Bioscience, Inc., the ... cellular bioenergetics, today announced it will present data with the ... Flux Analyzer in revealing the effects of KSR1 and nutrients ... The data will appear in two posters at the AACR ...
... , NEW YORK, Sept. 9 ... Vice President and General Manager of Informatics at Thermo Fisher ... HUNT Research Center and Biobank, about data integration: the benefits ... life sciences companies. , , ...
... , WATERTOWN, Mass., Sept. 9 EnVivo Pharmaceuticals ... vice president and chief financial officer. DiPalma is responsible ... and operations. , , "EnVivo has grown ... to help better manage our broad pipeline and increasing business ...
Cached Biology Technology:Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference 2Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer 2
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
(Date:7/30/2014)... associate professor Andrew S. Mount, performed cutting-edge research on ... novel anti-fouling paint for ships and boats and also ... team,s findings, published in Nature Communications ... attaches to a wide variety of surfaces using highly ... underwater heavy-duty adhesive. , "In previous research, we were ...
Breaking Biology News(10 mins):Deep-sea octopus has longest-known egg-brooding period 2Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... professors are leading research teams that will work ... and the Caribbean to increase food production, improve ... change. The projects are part of the Sustainable ... Program (SANREM CRSP), a $15 million, five-year program ...
... study from Children,s Hospital Boston and the Boston-based Autism Consortium ... known as chromosomal microarray analysis, has about three times the ... (ASDs) than standard tests. Publishing in the April issue of ... that CMA become part of the first-line genetic work-up for ...
... WINSTON-SALEM, N.C. Vitamin D is quickly becoming the "go-to" ... to atherosclerosis. However, new evidence from a Wake Forest University ... those with low levels may have different effects based on ... do harm. The study is the first to ...
Cached Biology News:Researchers introducing sustainable agriculture practices to improve food security 2Researchers introducing sustainable agriculture practices to improve food security 3A better genetic test for autism 2A better genetic test for autism 3Vitamin D levels have different effects on atherosclerosis in blacks and whites 2Vitamin D levels have different effects on atherosclerosis in blacks and whites 3
... is most widely used in combination ... differentially stain nucleic acids following polyacrylamide ... solution, Pyronin Y stains RNA red, ... Chem comp: Dye content ...
... The loxP-cm-loxP cassette is ... prokaryotic cells. The prokaryotic promoter ... resistance is a slightly modified version ... higher transcription efficiency than the generally ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
Biology Products: